CollPlant Biotechnologies Ltd
corporate_fare Company Profile
CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 33 items for CLGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CLGN spans 6-K, SCHEDULE 13D/A, F-3.
Recent high-impact activity:
- CollPlant Ousts CEO Yehiel Tal, Names CFO Eran Rotem CEO and Halts Regenerative Medicine R&D
- LightSolver Lands Paid Israel Ministry of Defense Deal for Photonic Computing LPU
- CollPlant Closes $3.7M Private Placement; Warrants Add 1.48M Potential Shares
- CollPlant Secures $3.7M Private Placement to Advance LightSolver Supercomputing
- CollPlant Amends LightSolver Deal Terms, Discloses Going Concern and Q2 Loss
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 52,732 shares in CLGN as of the October 15, 2026 settlement, a 24.9% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 6, 2026, 15.9% of CLGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CLGN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-09.
31M Share Resale Registration · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CLGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.